Parabilis Medicines priced its initial public offering, raising $670 million in gross proceeds from the sale of 33.5 million shares at $20 per share.

The amount was priced above the company's initial estimated range, as it prepares to advance a novel drug class targeting proteins long considered beyond the reach of conventional medicine.

Parabilis also entered a concurrent private placement with Regeneron Pharmaceuticals, which agreed to purchase approximately $75 million in shares at $18 per share, or 90% of the IPO price, in connection with a separate research collaboration between the two companies.¹

The Regeneron private placement is tied to a collaboration focused on developing Antibody-Helicon Conjugates, a hybrid approach combining antibody targeting with Helicon payloads designed to modulate intracellular proteins, extending the platform's potential applicability beyond Parabilis's internal pipeline.¹

Combined, the transactions are expected to deliver roughly $745 million in gross proceeds, with Parabilis expected to begin trading on the Nasdaq Global Select Market under the ticker "PBLS" on June 10 and an expected offering close date of June 11.¹

What is Parabilis and what does its platform do?

Parabilis was founded in 2015 on technology licensed from the laboratory of Greg Verdine, PhD, at Harvard University and has since built what it calls the Helicon discovery platform, a proprietary approach to engineering stabilized helical peptides capable of binding and modulating proteins that have historically been inaccessible to both small molecules and biologics.^2,3

The core problem the platform addresses is fundamental to drug discovery: an estimated 80% of biologically validated disease targets are considered undruggable, largely because they reside inside cells and present flat protein-interaction surfaces. Parabilis says this makes Helicons the only modality currently capable of consistently accessing this class of targets.³

The platform integrates AI- and physics-based computational modeling with high-throughput peptide synthesis and screening.³ Over a decade of development, the company has generated datasets comprising millions of data points across hundreds of thousands of Helicons, which power a continuous learning loop across all stages of drug discovery.

What is zolucatetide?

Parabilis's lead asset, zolucatetide, is described as the first drug candidate to directly inhibit the interaction between beta-catenin and the TCF family of transcription factors, the central node of the Wnt/beta-catenin signaling pathway, which drives aberrant cell proliferation across a broad range of tumor types.² For investors, the IPO represents not only a bet on zolucatetide's clinical trajectory, but also whether Helicons can deliver on the broader promise of reaching the vast undruggable proteome that has resisted decades of pharmaceutical effort.

Who is leading the company?

Parabilis is led by Mathai Mammen, MD, PhD, who previously served as global head of R&D and a member of the executive committee at Johnson & Johnson, where his team secured global approvals for nine medicines across oncology, immunology, and neuroscience. In total, Mammen has led the discovery or development of 19 approved medicines.³

Since its founding, Parabilis has raised over $800 million from investors including ARCH Venture Partners, Cormorant Asset Management, Fidelity Investments, GV, and RA Capital.³

Sources

1. Parabilis Medicines Announces Pricing of Upsized Initial Public Offering Parabilis Medicines June 9, 2026 https://www.globenewswire.com/news-release/2026/06/10/3309413/0/en/parabilis-medicines-announces-pricing-of-upsized-initial-public-offering.html?_gl=1*ofscib*_up*MQ..*_ga*MTAzNDg0NTQzMy4xNzgxMDk2NTQ3*_ga_B6167QB2TF*czE3ODEwOTY1NDckbzEkZzAkdDE3ODEwOTY1NDckajYwJGwwJGgxMTIzNjc0Mjk2*_ga_ERWPGTJ5X8*czE3ODEwOTY1NDckbzEkZzAkdDE3ODEwOTY1NDckajYwJGwwJGgw
2. United States Securities and Exchange Commission Amendment No. 3 To Form S-1 Registration Statement Securities and Exchange Commission June 9, 2026 https://www.sec.gov/Archives/edgar/data/1657677/000119312526262880/ck0001657677-20260609.htm
3. United States Securities and Exchange Commission Form S-1 Registration Statement Securities and Exchange Commission May 19, 2026 https://www.sec.gov/Archives/edgar/data/1657677/000119312526230994/ck0001657677-20260519.htm
4. Parabilis Medicines prices IPO at $20 per share, raises $670 million Investing.com June 9, 2026 https://www.investing.com/news/stock-market-news/parabilis-medicines-prices-ipo-at-20-per-share-raises-670-million-432SI-4734250